Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
January 3, 2022Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today...
-
November 10, 2021Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and...
-
– U.S. and Japan commercial teams fully staffed ahead of potential launches of efgartigimod in generalized myasthenia gravis (gMG) – – Signed partnership agreement with Medison for distribution...
-
October 21, 2021Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and...
-
Additional data from Phase 3 ADAPT trial demonstrate consistent depth of response across first two treatment cycles as measured by minimal symptom expression Additional ADAPT data also show...
-
September 3, 2021Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and...
-
Validation initiates formal evaluation of application which started on August 19, 2021; decision expected mid-2022If approved, efgartigimod will be the first-and-only approved FcRn antagonist in...
-
August 4, 2021Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and...
-
- Completion of enrollment expected by year-end for ADAPT-SC and ADVANCE (IV) trials of efgartigimod; topline data for both trials expected in first half of 2022 - Introduced “argenx 2025”...
-
July 22, 2021Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and...